Cytori Therapeutics Director Buys $18,105 in Stock (CYTX)
Cytori Therapeutics (NASDAQ:CYTX) Director David Rickey bought 7,100 shares of Cytori Therapeutics stock on the open market in a transaction dated Thursday, September 12th. The stock was purchased at an average price of $2.55 per share, with a total value of $18,105.00. Following the completion of the purchase, the director now directly owns 6,100 shares of the company’s stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
A number of analysts have recently weighed in on CYTX shares. Analysts at Roth Capital initiated coverage on shares of Cytori Therapeutics (NASDAQ:CYTX) in a research note to investors on Tuesday, September 10th. They set a “buy” rating on the stock. Analysts at Zacks downgraded shares of Cytori Therapeutics (NASDAQ:CYTX) from an “outperform” rating to a “neutral” rating in a research note to investors on Tuesday, July 16th. They now have a $2.90 price target on the stock.
Shares of Cytori Therapeutics (NASDAQ:CYTX) traded down 1.20% on Monday, hitting $2.47. The stock had a trading volume of 327,781 shares. Cytori Therapeutics has a 1-year low of $2.09 and a 1-year high of $4.93. The stock’s 50-day moving average is $2.43 and its 200-day moving average is $2.51. The company’s market cap is $166.1 million.
Cytori Therapeutics (NASDAQ:CYTX) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by $0.03. The company had revenue of $6.00 million for the quarter, compared to the consensus estimate of $2.88 million. On average, analysts predict that Cytori Therapeutics will post $-0.42 earnings per share for the current fiscal year.
Cytori Therapeutics, Inc develops cell therapies based on autologous adipose-derived stem and regenerative cells (NASDAQ:CYTX) to treat cardiovascular disease and repair soft tissue defects.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.